Securities code: Suzhou Zelgen Biopharmaceuticals Co.Ltd(688266) securities abbreviation: Suzhou Zelgen Biopharmaceuticals Co.Ltd(688266) Announcement No.: 2022038 Suzhou Zelgen Biopharmaceuticals Co.Ltd(688266)
Plan for issuing A-Shares to specific objects in 2021
Announcement of revised instructions
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear legal responsibility for the authenticity, accuracy and integrity of its contents according to law.
Suzhou Zelgen Biopharmaceuticals Co.Ltd(688266) (hereinafter referred to as “the company”) held the first meeting of the second board of directors of the company on May 19, 2022, deliberated and approved the relevant proposals of the company on adjusting some matters of issuing A-Shares to specific objects, and revised the contents of the plan for issuing A-Shares to specific objects. The main information of this plan revision is described as follows:
Revision of sections of the plan
1. Updated the status of deliberation on matters related to the issuance of shares to specific objects and the status of tips on major matters; 2. Revised the total amount of funds raised by issuing shares to specific objects and the investment projects of funds raised
1、 Basic information of the issuer 1. Updated the telephone number of the issuer; 2、 The issuance of shares to specific objects 2 revised the background and purpose of the issuance of shares to specific objects; 3. Amendment III. The issuance of shares to specific objects this time has set the first section of the issuance of shares to specific objects, and the scale and purpose of the funds raised from the summary ticket of the scheme to specific objects this time; 4. 5. The issuance of shares to specific objects updates the shareholding ratio of controlling shareholders and actual controllers before and after the issuance of shares to specific objects; 5. Vi. the approval of this issuance and the consideration of relevant matters related to the issuance of shares to specific objects and the procedures that need to be submitted for approval have been revised
1、 The plan for the use of the raised funds 1. Revised the section II of the board of directors on the use of the investment of the raised funds, the scale of the raised funds and the feasibility of the use of the raised funds; 2. Fourth, according to the latest situation of the company, the investment of the raised funds belongs to the necessity and feasibility of the implementation of Kexin’s raised investment projects, and the main business in the field of technological innovation; 3. Updated the acquisition of land certificate for raising investment projects
1、 After the issuance, the company’s business and capital 1. Revised the third section of the issuance to specific objects, the board of directors on the asset integration plan and the amendment of the articles of association, and the purpose of the raised funds of the bank’s shares; 2. The discussion and situation of the impact of the issuance on the company, the analysis of the issuance of shares to specific objects and the changes of business structure are updated in the shareholder structure and senior management structure. The controlling shareholders and actual control before and after the issuance. II. The shareholding proportion of the company’s financial petitioners after the issuance; 3. Revised edition
Revision of sections of the plan
Conditions, profitability and changes in cash flow, issuance, use of raised funds, public movement and risks related to the company’s products
6、 Risks related to this stock issuance
explain
2、 Cash dividends of the company in recent three years and 1. Updated the implementation of the company’s profit distribution policy in Section IV of the company’s profit distribution policy in 2021, and implemented the cash dividends and profit distribution policy. 4. Undistributed profits of the company in recent three years; 2. Updated the use arrangement of the company as of December 31, 2021, and the accumulated undistributed profits of the company
1. Updated the issue to specific objects I. The impact of the issue on the company’s earnings per share and the impact of the shares on the company’s earnings per share Section V the calculation of the impact of the issue to specific objects; 2. Revised the current diluted spot return of A-Shares issued this time. IV. the investment project of the raised funds and the report of the raised funds issued by specific objects analyze the relationship between the company’s existing business and the purpose of the company; 3. Updated the number and structure of personnel, technology and municipal staff of the company’s R & D personnel raising and investment project; 4. Revise the reserve situation of the field and other aspects, and describe the technical platform; 5. Updated the company’s patents
According to the authorization of the company’s second extraordinary general meeting in 2021, the revised plan does not need to be submitted to the company’s general meeting for deliberation.
It is hereby announced.
Suzhou Zelgen Biopharmaceuticals Co.Ltd(688266) board of directors may 20, 2022
